Multidrug treatment for COVID-19

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the COVID-19 pandemic.
• Specific antiviral treatments for COVID-19 were initially limited, necessitating exploration of alternative therapeutic strategies.

Purpose of the Study:

• To evaluate the potential of drug repurposing as a strategy for identifying COVID-19 treatments.
• To review the efficacy of existing drugs and multidrug therapies against SARS-CoV-2.

Main Methods:

• Literature review of drug repurposing strategies for COVID-19.
• Analysis of studies examining the efficacy of individual drugs (e.g., chloroquine, hydroxychloroquine, doxycycline, azithromycin, ivermectin) against SARS-CoV-2.
• Examination of successful multidrug therapy combinations.

Main Results:

• Several approved drugs, including hydroxychloroquine, azithromycin, doxycycline, and ivermectin, have demonstrated efficacy in inhibiting SARS-CoV-2.
• Multidrug regimens, such as hydroxychloroquine with azithromycin, or doxycycline with ivermectin, have been successfully administered.
• The differing mechanisms of action among repurposed drugs contribute to the efficacy of combination therapies.

Conclusions:

• Drug repurposing is a time-saving, cost-effective, and low-risk approach for discovering COVID-19 therapeutics.
• Multidrug therapy for COVID-19 is effective due to synergistic or additive effects and may mitigate the development of drug resistance.
• Repurposed medications represent a viable option for managing COVID-19, especially in resource-limited settings.